Proprotein Convertase Subtilisin/Kexin Type 9 and Systemic Inflammatory Biomarker Pentraxin 3 for Risk Stratification Among STEMI Patients Undergoing Primary PCI

Proprotein Convertase Subtilisin/Kexin Type 9 and Systemic Inflammatory Biomarker Pentraxin 3 for Risk Stratification Among STEMI Patients Undergoing Primary PCI

Xiaoxiao Zhao,1,* Li Song,1,* Ying Wang,1,* Jiannan Li,1 Jinying Zhou,1 Runzhen Chen,1 Chen Liu,1 Peng Zhou,1 Zhaoxue Sheng,1 Yi Chen,1 Hanjun Zhao,1 Hongbing Yan2 1Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Peking Union Medical Col...

Full description

Saved in:
Bibliographic Details
Main Authors: Zhao X, Song L, Wang Y, Li J, Zhou J, Chen R, Liu C, Zhou P, Sheng Z, Chen Y, Zhao H, Yan H
Format: article
Language:EN
Published: Dove Medical Press 2021
Subjects:
pentraxin-3
pcsk9
plaque morphology characteristics
optical coherence tomography
major adverse cardiovascular events
st-segment elevation myocardial infarction
Pathology
RB1-214
Therapeutics. Pharmacology
RM1-950
Online Access:https://doaj.org/article/dcd7a6b67a874af2b67e281f68bbbf4e
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/dcd7a6b67a874af2b67e281f68bbbf4e

Similar Items